Structured around activating the human gut microbiota to treat chronic diseases, Novome Biotechnologies, Inc. is a biotechnology company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria. Effectively enabling f living therapeutics - designated Genetically Engineered Microbial Medicines (GEMMs) - the firm is Novome is its proprietary GEMMs platform to develop a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones: a preclinical program in hyperoxaluria. Intent is subsequently to expand to otherindications the firm's efforts to use its proprietary synthetic biology platform
